177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib
for treatment of patients with somatostatin receptor positive tumours detected by
68Ga-DOTA-TATE/TOC PET. The combination of a PARP inhibitor that will specifically target the
repair mechanism, with ionising radiation causing SSB's might overcome the repair dependent
survival of the tumour cells, making them more sensitive to β-emission and increase the
probability of tumour cell death.